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Introduction: Patients with non–small-cell lung cancer (NSCLC) 
with somatic activating mutations of the epidermal growth factor 
receptor gene (EGFR mutations) generally respond to EGFR tyro-
sine kinase inhibitors (EGFR-TKIs). β-Catenin is a key component 
of the Wnt/β-Catenin signal and is an important oncogene that is 
involved in the pathogenesis and progression of malignant tumors, 
especially cancer stem cells.
Methods and Results: We found that EGFR-mutated NSCLC 
cell lines exhibited a high expression level of β-Catenin, com-
pared with cell lines with the wild-type EGFR gene, and XAV939 
(a β-Catenin inhibitor) enhanced the sensitivities to EGFR-TKI 
in EGFR-mutated NSCLC cell lines. In EGFR-mutated NSCLC 
cell lines with the acquired resistance threonine-to-methionine 
mutation in codon 790 (T790M) mutation, XAV939 enhanced 
the sensitivity of the cells to an irreversible EGFR-TKI but 
not a reversible EGFR-TKI. The combination of XAV939 and 
EGFR-TKIs strongly inhibited the β-Catenin signal and strongly 
decreased the phosphorylation of EGFR, compared with the use 
of EGFR-TKIs alone, suggesting an interaction between EGFR 
and the β-Catenin signal. The stem cell-like properties of the 
EGFR-mutated cell line carrying the T790M mutation were 
inhibited by XAV939 and BIBW2992 (an irreversible EGFR-
TKI). Furthermore, the stem cell-like properties were strongly 
inhibited by a combination of both the agents. A xenograft study 
demonstrated that β-Catenin knockdown enhanced the antitumor 
effect of BIBW2992 in the EGFR-mutated NSCLC cell line car-
rying the T790M mutation.
Conclusion: Our findings indicate that β-Catenin might be a novel 
therapeutic target in EGFR-mutated NSCLC carrying the T790M 
mutation.
Key Words: Non–small-cell lung cancer, Epidermal growth factor 
receptor T790M mutation, Epidermal growth factor receptor tyrosine 
kinase inhibitor, β-Catenin, Stem cell-like properties.
(J Thorac Oncol. 2015;10: 93–101)
Lung cancer is the leading cause of cancer-related death in the developed world.1 Non–small-cell lung cancer 
(NSCLC) accounts for approximately 80% of the lung can-
cers and the prognosis of advanced NSCLC remains very poor 
despite advances in the treatment.2
One promising treatment strategy involves the further 
subdivision of NSCLC into clinically relevant molecular sub-
sets, according to a classification schema based on specific so-
called oncogenic driver mutations. These mutations occur in 
genes that encode signal proteins crucial for cellular prolifera-
tion and survival. Thus, cancer might rely on the expression 
of these single-mutant oncogenes for survival. This concept 
is also called oncogene addiction.3 The epidermal growth fac-
tor receptor (EGFR) is recognized as an important molecular 
target in cancer therapy,4 and somatic activating mutations 
of the EGFR gene (EGFR mutations) are one type of onco-
genic driver mutation in NSCLC.5 Patients with NSCLC with 
EGFR mutations generally respond to EGFR tyrosine kinase 
inhibitors (EGFR-TKIs).6–11 Although these patients respond 
dramatically to treatment, the majority eventually undergo 
disease progression,12 and the threonine-to-methionine muta-
tion in codon 790 (T790M) in exon 20 of the EGFR gene is 
the most common type of acquired resistance mutation.13–15
β-Catenin is a key component of the Wnt/β-Catenin sig-
nal and is an important oncogene that is involved in the patho-
genesis and progression of malignant tumors including lung 
cancer.16–18 Numerous studies indicate that the Wnt/β-Catenin 
signal analogously contributes to cancer progression through 
the maintenance of highly tumorigenic subpopulations of can-
cer cells called cancer stem cells.19–22 A previous article has 
reported that excessive activation of the Wnt/β-Catenin signal 
exists in approximately 50% of the human NSCLC cell lines.23 
Importantly, β-Catenin also interacts closely with the EGFR, 
phosphoinositide 3-kinase (PI3K)/murine thymoma viral onco-
gene (AKT) and mitogen-activated protein kinase (MAPK)/
extracellular signal-regulated kinase (ERK) signals,24 and a 
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positive correlation exists between the activated EGFR muta-
tions and the nuclear accumulation of β-Catenin in NSCLC.25 
Thus, β-Catenin may affect the efficacy of EGFR-TKI therapy 
by bypassing the stimulation of EGFR or its downstream sig-
naling.26–28 However, the influence of the β-Catenin signal in 
EGFR-mutated NSCLC carrying the T790M mutation has not 
been previously reported. Hence, this subject was investigated 
in the present study.
MATERIALS AND METHODS
Cell Culture
The HEK293 cell line (human embryonic kidney cell 
line) was maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Nissui Pharmaceutical, Tokyo, Japan) supple-
mented with 10% fetal bovine serum (FBS) (GIBCO BRL, 
Grand Island, NY). The A549 (wild-type EGFR gene), H1299 
(wild-type EGFR gene), PC-9 (EGFR exon 19 deletion), PC-9/
ZD (EGFR exon 19 deletion and exon 20 T790M), 11_18 
(EGFR exon 21 L858R), H1975 (EGFR exon 21 L858R and 
exon 20 T790M), and H3122 (EGFR wild-type and anaplas-
tic lymphoma kinase gene [ALK] rearrangement) cell lines 
(human NSCLC cell lines) were maintained in Roswell Park 
Memorial Institute (RPMI) 1640 medium with 10% FBS 
(Sigma-Aldrich, St. Louis, MO). All the cell lines were main-
tained in a 5% carbon dioxide-humidified atmosphere at 37°C.
Ligands and Reagents
EGF, basic fibroblast growth factor (bFGF), and Wnt3a 
were purchased from R&D Systems (Minneapolis, MN). 
AG1478 (a reversible EGFR-TKI) was purchased from Wako 
(Tokyo, Japan). BIBW2992 (an irreversible EGFR-TKI) and 
TAE684 (an ALK inhibitor) were purchased from Selleck 
Chemicals (Houston, TX). XAV939 (a β-Catenin inhibitor) 
and cisplatin (cis-diamminedichloroplatinum [CDDP]) were 
purchased from Sigma-Aldrich. For the in vitro studies, stock 
solutions were prepared in dimethyl sulfoxide. For the in vivo 
studies, BIBW2992 was suspended in a vehicle (0.5% methyl-
cellulose [w/v] in sterile water) for oral administration to mice 
bearing xenograft tumors.
Growth Inhibition Assay In Vitro
The growth-inhibitory effects of XAV939, CDDP, 
AG1478, BIBW2992, and TAE684 were examined using a 3, 
4, 5-dimethyl-2H-tetrazolium bromide assay (MTT; Sigma-
Aldrich), as described previously.29
Plasmid Construction, Viral Production, 
and Stable Transfectants
A short hairpin RNA (shRNA)-targeting CTNNB1 gene 
was constructed using oligonucleotides encoding small inter-
fering RNA directed against the CTNNB1 gene and a non-
specific target as follows: CTCAGATGGTGTCTGCTAT 
for CTNNB1 shRNA (shRNA-CTNNB1), and 
TTCTGGAATACGCTCGTTG for control shRNA (shRNA-
scramble). The oligonucleotides were cloned into an RNAi-
Ready pSIREN-RetroQZsGreen vector (Clontech, Palo Alto, 
CA). The viral production and stable transfectant methods 
that were used have been previously described.30 The viral 
vector and stable viral transfectant cell lines were designated 
as pSIREN-CTNNB1, pSIREN-Scr, H1975/sh-CTNNB1, and 
H1975/sh-Scr, respectively.
Antibody
Antibodies specific for EGFR, phospho-EGFR, 
β-Catenin, cluster of differentiation (CD) 44, cyclin D1, cel-
lular myelocytomatosis oncogene (cMYC), poly ADP-ribose 
plymerase (PARP), cleaved PARP, caspase 3, cleaved caspase 
3, and β-actin were obtained from Cell Signaling (Beverly, 
MA). An antibody specific for active β-Catenin was obtained 
from Millipore (Bedford, MA).
Western Blot Analysis
A Western blot analysis was performed as described pre-
viously.29 Briefly, subconfluent cells were washed with cold 
phosphate-buffered saline (PBS) and harvested with Lysis A 
buffer containing 1%Triton X-100, 20 mM Tris-HCl (pH 7.0), 
5 mM ethylenediaminetetraacetic acid, 50 mM sodium chlo-
ride, 10 mM sodium pyrophosphate, 50 mM sodium fluoride, 
1 mM sodium orthovanadate and a protease inhibitor mix, 
Complete(Roche Diagnostics, Basel, Switzerland). Whole-cell 
lyses were separated using sodium dodecyl sulfate-PAGE and 
were blotted onto a polyvinylidene fluoride membrane. After 
blocking with 3% bovine serum albumin in a tris-buffered saline 
buffer (pH 8.0) with 0.1% Tween-20, the membrane was probed 
with the primary antibody. After rinsing twice with tris-buffered 
saline buffer, the membrane was incubated with a horseradish 
peroxidase-conjugated secondary antibody and washed, fol-
lowed by visualization using an enhanced chemiluminescence 
(ECL) detection system (GE Healthcare, Buckinghamshire, 
United Kingdom) and LAS-3000 (Fujifilm, Tokyo, Japan). 
When the influence of the ligands was evaluated, the cultured 
medium was replaced with FBS-free medium 6 hours before 
exposure to the ligands. An inhibitor, when used, was added 30 
minutes before the ligand stimulation.
Sphere Formation Assay
A total of 30,000 of cells were plated in six-well plates 
with a low-attachment surface and were then cultured in 
serum-free DMEM/F12 (Invitrogen, Carlsbad, CA) supple-
mented with 20 ng/ml EGF and 10 ng/ml bFGF in the pres-
ence of inhibitors for 48 hours (XAV939, 1 μM; BIBW2992, 
0.05 μM; or a combination of both). The number of spheres 
exceeding 20 μm in size was counted for each well under a 
microscope. The experiment was performed in triplicates.
Cell Cycle Distribution Analysis
The cell cycle analyses were performed as described 
previously.31 Briefly, the cell line was exposed to the inhibitors 
(XAV939, 1 μM; BIBW2992, 0.05 μM; or a combination of 
both) for 48 hours. The cells were harvested by trypsinization and 
fixed with cold 70% ethanol at 4°C for 30 minutes. Then, the cells 
were washed twice with PBS and were stained using propidium 
iodide (PI)/RNase Staining Buffer (BD Biosciences, San Jose, 
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CA) at room temperature for 15 minutes. The cells were analyzed 
using a flow cytometer (BD FACSCalibur; BD Biosciences), and 
the cell cycle analysis was performed using ModFit LT software. 
The experiment was performed in triplicates.
Annexin V Binding Apoptosis Analysis
The Annexin V binding apoptosis analyses were per-
formed as described previously.30 Briefly, the cells were 
exposed to the inhibitors (XAV939, 1μM; BIBW2992, 0.05 
μM; or a combination of both) for 48 hours, then the bind-
ing of Annexin V and PI to the cells was measured using 
an fluorescein isothiocyanate (FITC) Annexin V Apoptosis 
Detection Kit I (BD Biosciences) according to the manufac-
turer’s instructions. The cells were harvested using accutase 
and were stained with FITC Annexin V and PI at room tem-
perature for 15 minutes. The cells were then analyzed using 
a flow cytometer and Cell Quest software (BD Biosciences). 
The experiment was performed in triplicates.
Xenograft Studies
Nude mice (Bagg albino [BALB]/c nu/nu; 6-week-old 
females; CLEA Japan, Tokyo, Japan) were used for the in vivo 
studies and were cared for in accordance with the recommenda-
tions for the Handling of Laboratory Animals for Biomedical 
Research compiled by the Committee on Safety and Ethical 
Handling Regulations for Laboratory Animals Experiments, 
Kinki University. The ethical procedures followed and met the 
requirements of the United Kingdom Coordinating Committee 
on Cancer Research guidelines. To evaluate the effect of 
BIBW2992, a suspension of 5 × 106 H1975 transfectant cells 
(in 50 μl PBS) with 50 μl of Matrigel were subcutaneously 
inoculated into nude mice (n = 7). The treatment was initiated 
when the tumors in each group of mice achieved an average 
volume of approximately 100 mm3. In the treatment groups, 
BIBW2992 (15 mg/kg) was administered by oral gavage daily 
for 28 days; the control animals received 0.5% methylcellulose 
as the vehicle. The tumor volume was calculated as the length 
× width2 × 0.5. The tumor formation and volume were assessed 
every 2 to 3 days. At the end of the experiment, the mice were 
killed and the xenografts were resected, fixed in 10% buffered 
formalin for 6 to 10 hours, and processed for histologic analy-
sis. The method was described previously.32
Immunohistochemical Analysis
The cancer cells undergoing apoptosis were detected 
using the terminal deoxynucleotidyl transferase-mediated 
dUTP nick end labeling (TUNEL) method and the in situ 
apoptosis detection TUNEL kit (TaKaRa, Shiga, Japan) 
according to the manufacturer’s recommended protocol, as 
described previously.30
Statistical Analysis
Continuous variables were analyzed using the Student’s 
t test, and the results were expressed as the average and SDs. 
The statistical analyses were two-tailed and were performed 
using Microsoft Excel (Microsoft, Redmond, WA). A p value 
of less than 0.05 was considered statistically significant.
RESULTS
Expression of β-Catenin and Sensitivity 
to XAV939 in Lung Cancer Cell Lines
To examine the expression of β-Catenin in lung cancer 
cell lines, we performed a Western blot analysis. The cell lines 
with the wild-type EGFR gene (A549 and H1299) had a low 
expression of β-Catenin and active β-Catenin (active form of 
β-Catenin, dephosphorylated on Ser37 or Thr41). In contrast, 
the EGFR-mutated NSCLC cell lines (PC-9, PC-9/ZD, 11_18, 
and H1975) had a high expression of β-Catenin and active 
β-Catenin (Fig. 1A). This result supports the findings of a pre-
vious study showing that a positive correlation exists between 
activated EGFR mutations and the nuclear accumulation of 
β-Catenin in NSCLC.25 Despite the high expression, the lung 
cancer cell lines, including the EGFR-mutated cell lines, were 
not very sensitive to XAV939 (Fig. 1B).
XAV939 Enhanced the Sensitivity to EGFR-
TKIs in EGFR-Mutated NSCLC Cell Lines
Next, we examined the synergistic effect of XAV939 
using several reagents. XAV939 did not influence the sensitiv-
ity to the cytotoxic agent CDDP in either the A549 (wild-type 
FIGURE 1.  Expression of β-Catenin and sensitivity to its inhib-
itor, XAV939. A, expression of β-Catenin and active β-Catenin. 
The expression was determined using a Western blot analysis, 
and β-actin was used as an internal control. EGFR-mutated 
NSCLC cell lines (PC-9, 11_18, PC-9/ZD, and H1975) had high 
expression levels, compared with cell lines with the wild-type 
EGFR gene (HEK293, A549, and H1299), (B), sensitivities to 
XAV939. The growth-inhibitory effect was examined using an 
MTT assay. The experiment was performed in triplicate. The 
50% inhibitory concentrations of the A549, PC-9, PC-9/ZD, 
and H1975 cell lines were 164, 100, 27, and 57 μM, respec-
tively. The cell lines, including the EGFR-mutated NSCLC cell 
lines, were not very sensitive to the inhibitor despite their high 
expression levels. Lines, mean of independent triplicate experi-
ments. NSCLC, non–small-cell lung cancer.
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EGFR gene) or the PC-9 (EGFR exon 19 deletion) cell lines 
(Fig. 2A, B). XAV939 also did not also influence the sen-
sitivity to a reversible EGFR-TKI, AG1478, in the A549 
and H3122 (wild-type EGFR gene) cell lines (Fig. 2A, E), 
whereas it enhanced the sensitivity to AG1478 in the PC-9 
and the 11_18 (EGFR exon 21 L858R) cell lines (Fig. 2B). In 
the PC-9/ZD (EGFR exon 19 deletion and exon 20 T790M) 
and the H1975 cell lines (EGFR exon 21 L858R and exon 
20 T790M), however, XAV939 did not enhance the sensitiv-
ity to AG1478 (Fig. 2C, D). In contrast, XAV939 enhanced 
FIGURE 2.  Synergistic effect of XAV939 in NSCLC cell lines. The growth-inhibitory effect was examined using an MTT assay. 
The experiment was performed in triplicate, and dimethyl sulfoxide (DMSO) was used for the control. To evaluate the synergistic 
effect, the concentrations of XAV939 (a β-Catenin inhibitor), CDDP, AG1478 (a reversible EGFR-TKI), BIBW2992 (an irreversible 
EGFR-TKI), and TAE684 (an ALK inhibitor) that were used were 1, 300, 0.01, 0.05, and 0.02 μM, respectively. A, synergistic effect 
in the A549 cell line (wild-type EGFR gene). XAV939 alone did not inhibit the proliferation and did not enhance the inhibitory 
effects of CDDP and AG1478. In other words, XAV939 did not enhance the sensitivities to either CDDP or AG1478 in the A549 
cell line, (B), synergistic effect in the PC-9 cell line (EGFR exon 19 deletion). XAV939 alone did not inhibit the proliferation and 
did not enhance the sensitivity to CDDP, similar to the results obtained in the A549 cell line, but XAV939 greatly inhibited the 
proliferation when used in combination with AG1478, compared with AG1478 alone. In other words, XAV939 enhanced the 
sensitivity to AG1478. In the 11_18 cell line (EGFR exon 21 L858R), a similar synergistic effect was observed (data not shown), 
(C), synergistic effect in the PC-9/ZD cell line (EGFR exon 19 deletion and exon 20 T790M). XAV939 alone did not inhibit the 
proliferation, and the inhibitory effect was not enhanced when XAV939 was used in combination with AG1478. In contrast, 
XAV939 greatly inhibited the proliferation when used in combination with BIBW2992, compared with BIBW2992 alone. In other 
words, XAV939 enhanced the sensitivity to BIBW2992, (D), synergistic effect in the H1975 cell line (EGFR exon 21 L858R and 
exon 20 T790M). XAV939 alone slightly inhibited the proliferation, but the inhibitory effect was not enhanced when XAV939 
was used in combination with AG1478. In contrast, XAV939 greatly inhibited the proliferation when used in combination with 
BIBW2992, compared with BIBW2992 alone. In other words, XAV939 enhanced the sensitivity to BIBW2992, (E), synergistic 
effect in the H3122 cell line (wild-type EGFR gene and ALK rearrangement). XAV939 alone slightly inhibited the proliferation, but 
the inhibitory effect was not enhanced when used in combination with either AG1478 or TAE684. AG, AG1478; XAV, XAV939; 
BIBW, BIBW2992; TAE, TAE684; Columns, mean of independent triplicate experiments; bars, SD; n.s., not significant; *p < 0.05.
97Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015  EGFR T790M Mutation and β-Catenin
the sensitivity to an irreversible EGFR-TKI, BIBW2992, in 
the PC-9/ZD and the H1975 cell lines (Fig. 2C, D). Finally, 
in the H3122 cell line (wild-type EGFR gene and ALK rear-
rangement [another driver mutation in NSCLC]), XAV939 did 
not enhance the sensitivity to the ALK inhibitor TAE684 (Fig. 
2E). These results indicate that β-Catenin inhibition affects 
the EGFR signal, in particular.
Interaction between EGFR and β-Catenin Signal
Since the effect of β-Catenin inhibition was observed in 
the EGFR-mutated NSCLC cell lines and with EGFR-TKIs, 
we investigated the EGFR signal using a Western blot analy-
sis. In the PC-9 cell line, the phosphorylation of EGFR was 
not influenced by XAV939 alone, whereas it was decreased by 
AG1478 alone. Moreover, AG1478 decreased the expression 
of active β-Catenin, along with the decreased phosphorylation 
of EGFR. The combination of XAV939 and AG1478 strongly 
decreased the phosphorylation of EGFR and the expression of 
active β-Catenin, compared with AG1478 alone (Fig. 3A). In 
the PC-9/ZD and H1975 cell lines, AG1478 did not influence 
the phosphorylation of EGFR and the expression of active 
β-Catenin. Even when used in combination with XAV939, 
AG1478 did not influence the phosphorylation of EGFR 
in the PC-9/ZD and H1975 cell lines (Fig. 3A). However, 
BIBW2992 alone decreased the phosphorylation of EGFR 
and the expression of active β-Catenin. The combination of 
XAV939 and BIBW2992 strongly decreased the phosphoryla-
tion of EGFR and the expression of active β-Catenin, com-
pared with BIBW2992 alone, similar to the results seen in the 
PC-9 cell line treated with AG1478 (Fig. 3B).
FIGURE 3.  Western blot analyses for EGFR signal and β-Catenin in PC-9, PC-9/ZD, H1975, and A549 cell lines. The concentra-
tions of XAV939 (a β-Catenin inhibitor), AG1478 (a reversible EGFR-TKI), and BIBW2992 (an irreversible EGFR-TKI) that were 
used were 1, 0.01, and 0.05 μM, respectively. β-actin was used as an internal control. A, influence of XAV939 and AG1478. 
In the PC-9 cell line (EGFR exon 19 deletion), the phosphorylation of EGFR was not influenced by XAV939 alone, whereas it 
was decreased by AG1478 alone. Moreover, AG1478 decreased active β-Catenin along with the decreased phosphorylation of 
EGFR. The combination of XAV939 and AG1478 strongly decreased the phosphorylation of EGFR and the expression of active 
β-Catenin, compared with AG1478 alone. In the H1975 cell line (EGFR exon 21 L858R and exon 20 T790M), AG1478 did not 
influence the phosphorylation of EGFR or the expression of active β-Catenin. Even when used in combination with XAV939, 
AG1478 did not influence the phosphorylation of EGFR, (B), influence of XAV939 and BIBW2992. In the PC-9/ZD and H1975 
cell lines, BIBW2992 decreased the phosphorylation of EGFR and the expression of active β-Catenin. The combination of 
XAV939 and BIBW2992 strongly decreased the phosphorylation of EGFR and the expression of active β-Catenin, compared with 
BIBW2992 alone, similar to the results observed in the PC-9 cell line treated with AG1478, (C), influence of Wnt3a in the A549 
cell line (wild-type EGFR gene). The cultured medium was replaced with FBS-free medium 6 hours before exposure to Wnt3a 
(100 ng/ml); 6 hours after ligand stimulation, the phosphorylation of EGFR was investigated. XAV939 (1 μM), when used, was 
added 30 minutes before the ligand stimulation. Wnt3a slightly increased the phosphorylation of EGFR, which was cancelled by 
XAV939, (D), Influence of Wnt3a in the PC-9 cell line (EGFR exon 19 deletion). The cultured medium was replaced with FBS-
free medium 6 hours before exposure to Wnt3a (100 ng/ml); 6 hours after ligand stimulation, the phosphorylation of EGFR was 
investigated. When used, XAV939 (1 μM) and AG1478 (0.01μM) were added 30 minutes before ligand stimulation. Wnt3a did 
not influence the phosphorylation of EGFR, which had already been phosphorylated. However, Wnt3a did increase the phos-
phorylation that had been inhibited by AG1478. In addition, the increased phosphorylation was inhibited by XAV939.
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XAV939 alone did not influence the phosphorylation 
of EGFR in the cell lines with phosphorylated EGFR, but it 
strongly decreased phosphorylation when used in combina-
tion with EGFR-TKI, compared with EGFR-TKI alone. Then, 
to examine whether β-Catenin influences the EGFR signal 
in cell line without phosphorylated EGFR, the phosphoryla-
tion of EGFR after Wnt3a stimulation was investigated. In the 
A549 cell line (unphosphorylated EGFR), the phosphoryla-
tion of EGFR after Wnt3a stimulation increased slightly, but 
the effect was cancelled by XAV939 (Fig. 3C). In the PC-9 
cell line (phosphorylated EGFR), Wnt3a did not increase the 
phosphorylation of EGFR but it did increase the phosphoryla-
tion that had been decreased by AG1478 (Fig. 3D). In addition, 
the increased phosphorylation was inhibited by XAV939 (Fig. 
3D). These results suggest that the EGFR and β-Catenin sig-
nals interact with each other, as previously reported (Fig. 4).24
Association of the β-Catenin Signal with Stem 
Cell-Like Properties in the H1975 Cell Line
Because the β-Catenin signal is associated with cancer 
stem cells,19–22 the influences of inhibitors on sphere formation, 
which is a representative stem cell assay,20 were investigated 
in the H1975 cell line. XAV939 or BIBW2992 alone inhibited 
sphere formation (Fig. 5A). Furthermore, the combination of 
both the agents greatly inhibited sphere formation, compared 
with the effects of each agent alone (Fig. 5A). In the spheres 
of the H1975 cell line, downstream expressions related to stem 
cell-like properties (CD44, cMYC, and cyclin D1) were also 
decreased by XAV939 or BIBW2992 alone and were greatly 
decreased by the combination of both the agents (Fig. 5B).
Combination of XAV939 and BIBW2992 
Decreased S Phase and Enhanced 
Apoptosis in the H1975 Cell Line
Next, we analyzed the cell cycle distribution and 
Annexin V binding apoptosis of the H1975 cell line after 
exposure to XAV939 and BIBW2992. Each of the single 
reagents decreased S phase and induced apoptosis, while the 
combination of these reagents greatly decreased the S phase 
and induced apoptosis (Fig. 5C, D). Western blot analyses for 
apoptosis-related molecules revealed that the combination of 
these agents also increased the levels of cleaved PARP and 
cleaved caspase 3 (Fig. 5E).
β-Catenin Knockdown Enhanced the Sensitivity 
to BIBW2992 in the H1975 Cell Line In Vivo
To perform a xenograft study, we created a β-Catenin 
or non-specific target knockdown H1975 cell line using 
a shRNA-targeting CTNNB1 gene or a nonspecific tar-
get (H1975/sh-CTNNB1 and H1975/sh-Scr, respectively) 
 (Fig. 6A). BIBW2992 exhibited an enhanced effect in H1975/
sh-CTNNB1, compared with H1975/sh-Scr (CTNNB1: 
205.6 ± 40.87 mm3 versus Scr: 342.2 ± 72.05 mm3; p = 0.035, 
on day 29) (Fig. 6B). TUNEL staining of the tumor specimens 
showed that apoptosis was increased in H1975/sh-CTNNB1 
cells (Fig. 6C).
DISCUSSION
EGFR mutations occur in 30% of the patients with 
NSCLC who are of East Asian ethnicity compared with 8% of 
the patients of other ethnicities.33 Despite dramatic responses 
to treatment with EGFR-TKIs, patients with NSCLC who 
harbor EGFR mutations will eventually experience disease 
progression as a result of the inevitable development of resis-
tance mechanisms, particularly, the T790M mutation, which is 
found in more than 50% of the patients who are treated with 
EGFR-TKIs.13–15 Irreversible ErbB family blockers are called 
second generation EGFR-TKIs and include BIBW2992, the 
preclinical activity of which has been shown to include EGFR-
mutated cell lines carrying the T790M mutation.34,35 However, 
the clinical trials of second generation EGFR-TKIs in patients 
with acquired resistance have demonstrated disappointing 
results.36–38 Therefore, there is an increasing need to develop 
new molecular targeted agents. In the present study, we found 
FIGURE 4.  Diagram for the proposed effects of 
β-Catenin on EGFR mutations. A, normal state. 
β-Catenin closely interacts with EGFR, (B), EGFR-
mutated state. The activated EGFR activates the 
β-Catenin signal. However, β-Catenin signal has a 
minimal influence on the EGFR signal, which has 
already been activated, (C), EGFR-mutated state with 
EGFR-TKI. EGFR-TKI inhibits the activated EGFR signal, 
resulting in the suppression of the β-Catenin signal. 
However, the remaining β-Catenin signal may activate 
the EGFR signal that had been inhibited by the EGFR-
TKI, (D), EGFR-mutated state with XAV939 and EGFR-
TKI. Both the β-Catenin signal and the EGFR signal are 
inhibited, resulting in the inhibition of the interaction. 
Therefore, the proliferation, survival, and stem cell-like 
properties are greatly suppressed.
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that the β-Catenin signal was activated in EGFR-mutated 
NSCLC cell lines, as previously reported,25 and was associ-
ated with stem cell-like properties. Furthermore, the inhibi-
tion of this signal enhanced the antitumor effect of BIBW2992 
against EGFR-mutated NSCLC carrying the T790M mutation. 
Although some previous studies have revealed that β-Catenin 
can affect the efficacy of EGFR-TKI therapy,26–28 this is the 
first report to show that the inhibition of the β-Catenin sig-
nal enhances the antitumor effect of BIBW2992 for EGFR-
mutated NSCLC carrying the T790M mutation.
An interaction between EGFR and the β-Catenin signal 
has been reported,24 and our experiments have demonstrated 
that EGFR-TKI alone inhibits the β-Catenin signal and that 
the combination of XAV939 and EGFR-TKI greatly inhibits 
both the β-Catenin signal and the EGFR signal, compared 
with XAV939 or EGFR-TKI alone. These results suggest 
that this synergistic effect comes not only from inhibiting the 
bypassing role of the β-Catenin signal, but also by inhibit-
ing the interaction (Fig. 4). In an EGFR-mutated NSCLC 
cell line, the β-Catenin signal does not activate the EGFR 
signal, which has been already activated, and XAV939 alone 
does not inhibit the already activated EGFR signal. In gen-
eral, reversible EGFR-TKIs cannot inhibit the EGFR signal in 
cells with the acquired resistance T790M mutation because of 
FIGURE 5.  Stem cell-like properties, cell cycle, and apoptosis in the H1975 cell line (EGFR exon 21 L858R and exon 20 T790M). 
The concentrations of XAV939 (a β-Catenin inhibitor) and BIBW2992 (an irreversible EGFR-TKI) that were used were 1 and 0.05 
μM, respectively. A, sphere formation of H1975 cell line. A total of 30,000 of cells were plated in six-well plates with a low attach-
ment surface, and the cells were cultured in serum-free DMEM/F12 supplemented with 20 ng/ml EGF and 10 ng/ml bFGF in 
the presence of inhibitors. The number of spheres exceeding 20 μm in size was counted for each well under a microscope. The 
experiment was performed in triplicates, and DMSO was used for the control. Treatment with XAV939 or BIBW2992 reduced the 
size and number of spheres (p = 0.042* and 0.043* respectively). The combination of these two agents further decreased the size 
and the number of spheres, compared with XAV939 or BIBW2992 alone (p = 0.046* and 0.013* respectively). Scale bar, 20 μm. 
Columns, mean of independent triplicate experiments; bars, SD; *p < 0.05, (B), Western blot analyses of the β-Catenin signal and 
its downstream expression in the spheres of H1975 cell line. β-actin was used as an internal control. The cell line was exposed to 
the inhibitors for 48 hours before the Western blot analyses. XAV939 or BIBW2992 alone suppressed the downstream expression 
(CD44, cMYC, and cyclin D1), and the combination of both the agents greatly suppressed the expression, (C), cell cycle distribu-
tion in the H1975 cell line. The cell line was exposed to the inhibitors for 48 hours. The cells were harvested, fixed, and stained 
using PI/RNase Staining Buffer. The cells were analyzed using a flow cytometer. The experiment was performed in triplicates, 
and DMSO was used for the control. XAV939 or BIBW2992 alone decreased S phase (p = 0.0024* and 0.0031*, respectively), 
and the combination of both the agents greatly decreased S phase, compared with XAV939 or BIBW2992 alone (p = 0.0029* 
and 0.0020*, respectively). Columns, mean of independent triplicate experiments; bars, SD; *p < 0.05, (D), annexin V binding 
apoptosis analyses. The cells were exposed to the inhibitors (XAV939, 1μM; BIBW2992, 0.05 μM; or a combination of both) for 
48 hours and were then harvested and stained with FITC Annexin V and PI. The cells were analyzed using a flow cytometer. The 
experiment was performed in triplicates, and DMSO was used for the control. XAV939 or BIBW2992 alone induced apoptosis (p = 
0.011* and 0.011*, respectively), and the combination of both the agents further induced apoptosis, compared with XAV939 or 
BIBW2992 alone (p = 0.018* and 0.015*, respectively). Columns, mean of independent triplicate experiments; bars, SD; *p < 0.05, 
(E), Western blot analyses for apoptosis-related molecules in the H1975 cell line. β-actin was used as an internal control. XAV939 or 
BIBW2992 alone increased the expression of cleaved PARP and cleaved caspase 3, and the combination of agents further increased 
these molecules, compared with XAV939 or BIBW2992 alone. C-PARP, cleaved PARP, C-caspase 3, cleaved caspase 3.
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their structure and affinity for ATP.13,39 Therefore, in the PC-9/
ZD and H1975 cell lines, which harbor the acquired resis-
tance T790M mutation, AG1478 (a reversible EGFR-TKI) 
did not inhibit the EGFR signal and XAV939 did not inhibit 
the already activated EGFR signal, resulting in no synergistic 
effect. In contrast, BIBW2992 (an irreversible EGFR-TKI) 
inhibited the EGFR signal and exhibited a synergistic effect 
in the PC-9/ZD and H1975 cell lines. Therefore, in EGFR-
mutated NSCLC carrying the T790M mutation, β-Catenin 
could become a novel therapeutic target when used in combi-
nation with irreversible EGFR-TKIs, such as BIBW2992, but 
not with reversible EGFR-TKIs. In addition, several recent 
studies have demonstrated that third-generation EGFR-TKIs, 
which are mutant-selective inhibitors, can overcome T790M-
mediated resistance.40,41 Therefore, β-Catenin might also 
become a potential therapeutic target in treatments combined 
with the use of these third-generation EGFR-TKIs.
Numerous studies have reported an association between 
cancer stem cells and chemotherapy resistance,19–22 and sev-
eral studies have examined the association between stem 
cell-like properties and EGFR-TKI resistance.42–44 Numerous 
studies indicate that the Wnt/β-Catenin pathway contributes 
to cancer stem cells.19–22 In the present study, we showed 
that the inhibition of the β-Catenin signal contributed to the 
inhibition of sphere formation, that is, stem cell-like proper-
ties, in the H1975 cell line, suppressing downstream CD44, 
cMYC, and cyclin D1. Although another previous study in 
which cyclin D1 was suppressed by EGFR-TKIs in the H1975 
cell line has been reported,45 our study is the first report to 
show that not only cyclin D1, but also the β-Catenin signal 
is associated with the antitumor effect of EGFR-TKIs in the 
H1975 cell line. A recent study has shown that first-line treat-
ment with BIBW2992 significantly prolonged survival, com-
pared with first-line platinum based chemotherapy, in patients 
with EGFR-mutated NSCLC, especially carrying the exon 19 
deletion, suggesting that NSCLC carrying the EGFR exon 19 
deletion might be more sensitive to BIBW2992 than to other 
EGFR-TKIs.46 Furthermore, these data raise the possibility 
that platinum based chemotherapy may make NSCLC car-
rying EGFR mutations less sensitive to second-line or later 
treatments with EGFR-TKIs. Reportedly, platinum-based che-
motherapy induces stem cell-like properties via the β-Catenin 
signal.47 Thus, the inhibition of β-Catenin may enable such 
resistance to be overcome.
In conclusion, we found that the inhibition of the 
β-Catenin signal enhanced the sensitivity to EGFR-TKIs in 
EGFR-mutated NSCLC, an effect that was seen using an irre-
versible EGFR-TKI and EGFR-mutated NSCLC carrying the 
T790M mutation. This synergistic effect arose from the inhi-
bition of the interaction between EGFR and the β-Catenin 
signal. In addition, the inhibition of β-Catenin signal contrib-
uted to the suppression of the stem cell-like properties, which 
are also related to EGFR-TKI resistance. Our findings indi-
cate that β-Catenin could become a novel therapeutic target 
for EGFR-mutated NSCLC carrying the T790M mutation.
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